Table 1.

Clinical characteristics of the patient and the control groups.

	Patient group (n = 103)	Control group (n = 114)	P
Mean age(yr)	46.4 ± 13.5	43.2 ± 13.2	.073
Sex
Female	52 (50.5%)	56 (49.1%)	.841
Male	51 (49.5%)	58 (50.9%)
CDAI
Inactive	63 (61.2%)
Mild	24 (23.3%)
Moderate	16 (15.5%)
Duration of disease
0–5 yr	31 (30.1%)
6–10 yr	25 (24.3%)
>10 yr	47 (45.6%)
Montreal Classification
A1	4 (3.9%)
A2	59 (57.3%)
A3	40 (38.8%)
L1	51 (49.5%)
L2	12 (11.7%)
L3	40 (38.8%)
B1	67 (65%)
B2	18 (17.5%)
B3	13 (12.6%)
Perineal disease	5 (4.9%)
Upper gastrointestinal disease	0 (0%)
Prior ileal or ileocolic resection	31 (30.1%)
Treatment of CD
5-ASA	52 (50.5%)
AZA	28 (27.2%)
Biologic + AZA	12 (11.7%)
Biologic agents	6 (5.8%)
Sulfasalazin	2 (1.9%)
5-ASA + AZA	2 (1.9%)
Sulfasalazin + AZA	1 (1%)

ASA = 5-aminosalicylic acid, AZA = azathioprine, CD = Crohn’s disease, CDAI = Crohn’s disease activity index.